Core Viewpoint - Haitong International maintains an "outperform" rating for CSPC Pharmaceutical Group (01093) with a target price of HKD 11.34, noting a revenue decline in the first three quarters but signs of recovery in Q3, with a 10% quarter-on-quarter growth in prescription drug revenue and a 27% year-on-year increase in net profit attributable to shareholders [1][2]. Financial Performance - For the first nine months of 2025, CSPC achieved revenue of CNY 19.9 billion, a 12% year-on-year decline, with prescription drug revenue at CNY 15.5 billion (down 17%), API revenue at CNY 3 billion (up 10%), and functional foods and other businesses at CNY 1.4 billion (up 11%) [2]. - The gross margin was 65.6%, down 4.9 percentage points year-on-year; R&D expenses were CNY 4.2 billion (up 8%), with an R&D expense ratio of 21.0% (up 3.9 percentage points); the sales expense ratio was 24.1% (down 5.1 percentage points) [2]. - In Q3 2025, CSPC reported revenue of CNY 6.6 billion, a 3% year-on-year increase and a 6% quarter-on-quarter increase, with prescription drug revenue at CNY 5.2 billion (up 2% year-on-year, up 10% quarter-on-quarter) [2]. Prescription Drug Business - In Q3 2025, all segments of the prescription drug business showed improvement, confirming the bottom of the fundamentals, with total prescription drug revenue of CNY 4.7 billion and drug revenue of CNY 4.7 billion (up 8% quarter-on-quarter) [3]. - Specific revenue breakdown includes: - Neurological system: CNY 1.91 billion (down 4% year-on-year, up 4% quarter-on-quarter) - Oncology: CNY 590 million (down 47% year-on-year, up 19% quarter-on-quarter) - Anti-infection: CNY 830 million (down 9% year-on-year, up 12% quarter-on-quarter) - Cardiovascular: CNY 470 million (up 18% year-on-year, up 4% quarter-on-quarter) - Respiratory: CNY 320 million (up 73% year-on-year, up 28% quarter-on-quarter) - Metabolism: CNY 250 million (up 14% year-on-year, up 8% quarter-on-quarter) - Other therapeutic areas: CNY 360 million (up 26% year-on-year, down 4% quarter-on-quarter) [3]. - The company expects a 5% revenue growth in the second half of the year for the prescription drug segment (excluding authorized revenue) [3]. Asset Expansion and R&D Progress - The SYS6010 (EGFRADC) clinical trial is progressing well, with significant potential for external licensing; multiple technology platforms and products are also expected to expand internationally [4]. - Management plans to present clinical data for SYS6010 at major conferences next year and publish data in top academic journals [5]. - The small RNA platform has five assets entering clinical stages, focusing on liver-targeted and multi-target products, with plans for new products in weight loss and muscle gain to enter clinical trials next year [6]. - The PD-1/IL15 pipeline is a key focus, with over 90 patients enrolled in dose-exploration trials, showing promising safety and efficacy results [6].

Core Viewpoint - Haitong International maintains an "outperform" rating for CSPC Pharmaceutical Group (01093) with a target price of HKD 11.34, noting a revenue decline in the first three quarters but signs of recovery in Q3, with a 10% quarter-on-quarter growth in traditional medicine revenue and a 27% year-on-year increase in net profit attributable to shareholders [1]. Financial Performance - For the first nine months of 2025, CSPC achieved revenue of CNY 19.9 billion, a 12% year-on-year decline, with traditional medicine revenue at CNY 15.5 billion (down 17%), API revenue at CNY 3 billion (up 10%), and functional foods and other businesses at CNY 1.4 billion (up 11%) [1]. - The gross margin was 65.6%, down 4.9 percentage points year-on-year; R&D expenses were CNY 4.2 billion (up 8%), with an R&D expense ratio of 21.0% (up 3.9 percentage points); the sales expense ratio was 24.1% (down 5.1 percentage points) [1]. - The net profit attributable to shareholders for the first three quarters was CNY 3.5 billion, a 7% year-on-year decline [1]. Q3 Performance - In Q3 2025, CSPC reported revenue of CNY 6.6 billion, a 3% year-on-year increase and a 6% quarter-on-quarter increase, with traditional medicine revenue at CNY 5.2 billion (up 2% year-on-year, up 10% quarter-on-quarter) [2]. - The gross margin was 65.6%, down 2.1 percentage points year-on-year; R&D expenses were CNY 1.5 billion (up 12.3%), with an R&D expense ratio of 22.7% (up 1.8 percentage points); the sales expense ratio was 26.4% (down 2.4 percentage points) [2]. - The net profit attributable to shareholders for Q3 was CNY 960 million, a 27% year-on-year increase but a 10% quarter-on-quarter decline [2]. Traditional Medicine Business - In Q3, all segments of the traditional medicine business showed improvement, indicating a bottoming out of fundamentals, with traditional medicine revenue of CNY 4.7 billion and drug revenue of CNY 4.7 billion (up 8% quarter-on-quarter) [3]. - Specific revenue breakdown includes: - Neurological system: CNY 1.91 billion (down 4% year-on-year, up 4% quarter-on-quarter) - Oncology: CNY 590 million (down 47% year-on-year, up 19% quarter-on-quarter) - Anti-infection: CNY 830 million (down 9% year-on-year, up 12% quarter-on-quarter) - Cardiovascular: CNY 470 million (up 18% year-on-year, up 4% quarter-on-quarter) - Respiratory: CNY 320 million (up 73% year-on-year, up 28% quarter-on-quarter) - Metabolism: CNY 250 million (up 14% year-on-year, up 8% quarter-on-quarter) - Other therapeutic areas: CNY 360 million (up 26% year-on-year, down 4% quarter-on-quarter) [3]. - The company expects a 5% revenue growth in the traditional medicine segment (excluding authorized revenue) in the second half of the year compared to the first half [3]. Asset Expansion and R&D Progress - The SYS6010 (EGFRADC) clinical trial is progressing well, with significant potential for external licensing; multiple technology platforms and products are expected to expand internationally [4]. - Management plans to present clinical data for SYS6010 at major academic conferences next year and publish lung cancer clinical data in top journals [5]. - The small RNA platform has five assets entering clinical stages, focusing on liver-targeted and multi-target products, with plans for new products in weight loss and muscle gain to enter clinical trials next year [6]. - The PD-1/IL15 pipeline is a key focus, with over 90 patients enrolled in dose-exploration trials, showing promising safety and efficacy results [6].

"易中天"大涨。 A股市场今天（11月26日）上午整体走强，主要股指低开高走，创业板指涨近3%。截至中午收盘，上 证指数涨0.14%，深证成指涨1.61%，创业板指涨2.76%。盘面上，通信板块大涨逾5%，成为上午A股市 场主要亮点之一。 | 上证指数 | 深证成指 | 北证50 | | --- | --- | --- | | 3875.48 | 12982.74 | 1402.36 | | +5.45 +0.14% | +205.43 +1.61% | +5.53 +0.40% | | 科别20 | 创业板指 | 万得全A | | 1319.35 | 3063.09 | 6189.48 | | +17.19 +1.32% | +82.16 +2.76% +45.85 +0.75% | | | 沪深300 | 中证500 | 中证A500 | | 4527.22 | 7013.45 | 5441.06 | | +36.81 +0.82% +58.85 +0.85% +48.15 +0.89% | | | | 中证1000 | 深证100 | 中证红利 | | 7299.43 | 5709.57 | 5539. ...

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a strong performance, with key indices showing significant gains, driven by positive news regarding leading companies and favorable market conditions [1] Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 1.9%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 1.2%, both aiming for a third consecutive day of gains [1] - The performance of the innovative drug sector is supported by the anticipated interest rate cuts by the Federal Reserve, which have increased the probability of a 25 basis point cut in December from 40% to 80.9% [1] Group 2: Company Developments - Three-Six Pharmaceutical plans to spin off its Minoxidil brand, Mandi International, for a main board listing on the Hong Kong Stock Exchange [1] - The clinical trial application for ActRIIA/B antibody JMT206 injection by CSPC Pharmaceutical has been approved for obesity treatment [1] Group 3: Investment Opportunities - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is the first ETF-tracked index with a 100% "purity" focus on leading innovative drug companies in Hong Kong [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index consists of the 50 largest stocks in the pharmaceutical and health sector within the Stock Connect range, covering innovative drugs and medical devices [1] - The Hang Seng Innovative Drug ETF (159316) and the Hong Kong Stock Connect Medical ETF (513200) track these indices, providing investors with opportunities to capitalize on sector recovery [1]

Market Overview - A-shares showed overall strength on November 26, with major indices opening lower and then rising, particularly the ChiNext index which increased by nearly 3% [2] - By midday, the Shanghai Composite Index rose by 0.14%, the Shenzhen Component Index increased by 1.61%, and the ChiNext Index was up by 2.76% [3] Sector Performance - The communication sector was a standout performer, surging over 5%, marking it as a key highlight of the morning session in the A-share market [4] - Within the communication sector, notable stocks included: - Zhongji Xuchuang, which surged by 13.89% to reach 546.29 CNY per share, setting a new historical high [5] - Xinyi Sheng increased by 10.44% and Tianfu Communication rose by 6.87% [4] Stock Highlights - Multiple stocks experienced significant gains, with several hitting the daily limit up: - Special Information rose by 10.04% - Shida Group increased by 10.02% - Yongding Co. rose by 9.92% [5] - The electronics sector also saw gains, with an overall increase exceeding 2%, and stocks like Mingwei Electronics and Changguang Huaxin hitting the daily limit up [6] Trading Activity - The total trading volume reached 1.14 trillion CNY, with a predicted total of 1.78 trillion CNY, reflecting a decrease of 420 billion CNY [3] - Despite recent market fluctuations, individual stocks remained active, with several continuing to hit the daily limit up [7] Company Announcements - Shida Group announced a significant stock price increase over the past few trading days, with a cumulative rise of over 20% [8] - Guosheng Technology reported a stock price increase and highlighted potential risks associated with its recent investment activities [9][10] - Jinfeng Technology also noted a stock price increase and is in the process of planning an acquisition, with associated risks mentioned [12] Hong Kong Market - The Hong Kong market performed well, with the Hang Seng Index fluctuating around 26,000 points [13] - Notable stocks in the Hang Seng Index included Meituan-W and Stone Pharmaceutical Group, which saw significant gains [14] - Gaoya Optical experienced a dramatic rise, with intraday gains nearing 80%, attributed to a positive profit warning announcement [15]

Market Overview - The total trading volume in the market reached 1.14 trillion yuan, slightly lower than the same period the previous day, with over 2800 stocks rising [2] - The communication sector saw significant gains, particularly in optical modules, optical communication, and optical chips, while sectors like defense, banking, and media experienced pullbacks [2] Sector Performance - The top performing indices included: - Optical Modules (CPO) up 6.52% - Optical Chips up 4.80% - Optical Communication up 4.33% - Consumer Electronics Manufacturing up 2.86% [3] - In the Hong Kong market, major indices remained positive, with Meituan leading the Hang Seng Index with a rise of 5.85% [3] Notable Stocks - Long光华芯 (SH:688048) reached a price of 107.15 yuan, up 20.00%, with a trading volume of 27.52 billion yuan [6] - 中际旭创 (300308) hit a new high of 549.88 yuan per share, with a market capitalization exceeding 600 billion yuan [7] - Other notable gainers included 新易盛 (300502) and 剑桥科技 (603083), with increases of 10.44% and 7.54% respectively [7] Company News - Alibaba reported a 34% year-on-year increase in cloud revenue for Q2 of fiscal year 2026, with AI-related product revenue growing for nine consecutive quarters [9] - In the consumer electronics sector, new product launches from Huawei and Alibaba are expected to drive market momentum [12]

Market Overview - The A-share market saw all three major indices rise collectively, with the Shanghai Composite Index up by 0.14%, Shenzhen Component Index up by 1.61%, and ChiNext Index up by 2.76% as of the midday close [2] - The total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 1.1439 trillion yuan, a decrease of 39.2 billion yuan compared to the previous trading day [2] - Over 2,800 stocks in the market experienced gains [2] Sector Performance - The CPO sector continued to strengthen, with Longguang Huaxin hitting the daily limit [3] - The flu sector showed strong performance, with stocks like Yue Wannianqing and Huaren Health also hitting the daily limit, and Haiwang Biological experiencing a rapid surge to the limit within three minutes [3][4] - The pharmaceutical sector saw a collective explosion, driven by flu and innovative drug concepts, with several companies reaching the daily limit [4] Industry Catalysts - The arrival of the flu season has provided a strong catalyst for pharmaceutical stocks, with the China CDC reporting that flu activity is currently at a rising stage, particularly in southern provinces [6] - Companies like Zhenbaodao have responded to investor inquiries regarding their flu treatment drugs, which are currently in production and sale [7] - Shiyao Group announced that its self-developed siRNA drug has received FDA approval for clinical trials in the U.S. and is set to begin trials in China in 2025 [7] Macro Trends - According to Everbright Securities, the global economy is returning to a rate-cutting cycle, which is expected to benefit innovative assets [7] - The aging population globally is driving an increase in healthcare spending, expanding the global demand for pharmaceuticals [7] - China's pharmaceutical innovation is on the rise, with a growing share of the global pharmaceutical market expected to be captured by the Chinese industry [7] AI and Cloud Computing - The computing power hardware sector saw renewed activity, with stocks like Zhongji Xuchuang and Xinyi Sheng experiencing significant gains [8] - Alibaba Group reported a revenue of 247.795 billion yuan for Q2 of fiscal year 2026, exceeding market expectations with a year-on-year growth of 15% [9] - Alibaba's CEO highlighted the synergy between AI to B and AI to C strategies, which are expected to drive continued growth [9] - The AI cloud market in China is led by Alibaba Cloud, which is seen as a core driver of growth in cloud computing [9]

Market Overview - The A-share market showed a strong upward trend on November 26, with the Shanghai Composite Index rising by 0.14%, the Shenzhen Component Index increasing by 1.61%, and the ChiNext Index surging by 2.76% [1][2]. Sector Performance - The communication sector experienced significant gains, particularly in optical modules, optical communication, and optical chips, which saw collective activity. Other sectors such as electronics, pharmaceuticals, and building materials also reported increases, while sectors like defense, banking, and media experienced pullbacks [2][6]. Key Stock Movements - Notable stocks included Changguang Huaxin, which hit a 20% limit up, and several others like Xinyisheng and Yuanjie Technology that also saw substantial increases [6][8]. - Zhongji Xuchuang reached a peak price of 549.88 CNY per share, marking a new historical high, with a market capitalization exceeding 600 billion CNY [9]. Consumer Electronics Developments - In the consumer electronics sector, Saiwei Electronics surged over 18%, while Changying Precision rose more than 12%. Industrial Fulian also saw an increase of nearly 6% [11]. - Recent product launches, including Huawei's Mate 80 series and Alibaba's upcoming AI glasses, are expected to drive further growth in the industry [14]. Bond Market Activity - Vanke bonds continued to decline, with several bonds experiencing a drop of 20% or more, triggering temporary suspensions. This decline in bond prices has also affected Vanke's stock price, which reached a low of 6.00 CNY per share, the lowest since 2015 [15][16][18].

Market Performance - The Hang Seng Index increased by 0.46% at midday on November 26 [1] - The Hang Seng Tech Index rose by 0.51% [1] Sector Performance - Pharmaceutical stocks, paper stocks, innovative drugs, and electric equipment stocks showed significant gains [1] - China Eastern Airlines shares rose over 6% [1] - Meituan shares increased nearly 6% [1] - Hengrui Medicine shares rose over 5% [1] - Smoore International shares increased nearly 5% [1] - CSPC Pharmaceutical shares rose over 3% [1] Declining Stocks - NIO shares fell over 7% [1] - Chow Tai Fook and Huayi Brothers shares dropped over 6% [1] - China Shipbuilding Defense shares declined over 4% [1] - Bilibili shares decreased over 2% [1]

Group 1 - The core viewpoint of the news highlights the positive performance of the Hong Kong stock market, particularly driven by the strong earnings report from Alibaba Group, which reported revenues of approximately 247.8 billion yuan for the second fiscal quarter of 2026, reflecting a 15% year-on-year growth after excluding the impact of divested businesses, surpassing market expectations [1] - The Hong Kong stock market is expected to reach new highs in the fourth quarter, supported by a dual logic of improving fundamentals and continuous enhancement of liquidity, as stated by Guotai Junan Securities [1] - The technology sector in Hong Kong is anticipated to benefit from the AI industry cycle, becoming a core theme for year-end market performance [1] Group 2 - As of November 25, 2025, the top ten weighted stocks in the HSISC index include Alibaba-W, HSBC Holdings, Tencent Holdings, and others, collectively accounting for 55.68% of the index [1] - The HSISC index has shown a 0.46% increase, with notable gains from stocks such as Meituan-W, which rose over 6%, and others like CSPC Pharmaceutical Group and Shenzhou International, which increased by over 3% [1] - The HSISC ETF (520960) closely tracks the HSISC index, with Alibaba-W being the largest weighted stock, focusing on scarce investment opportunities in the Hong Kong market [2]